We estimated penetrance of actionable genetic variants and assessed near-term outcomes following return of results (RoR).
Participants (n = 2,535) with hypercholesterolemia and/or colon polyps underwent targeted sequencing of 68 genes and 14 single-nucleotide variants. Penetrance was estimated based on presence of relevant traits in the electronic health record (EHR). Outcomes occurring within 1-year of RoR were ascertained by EHR review. Analyses were stratified by tier 1 and non–tier 1 disorders.
Actionable findings were present in 122 individuals and results were disclosed to 98. The average penetrance for tier 1 disorder variants (67%; n = 58 individuals) was higher than in non–tier 1 variants (46.5%; n = 58 individuals). After excluding 45 individuals (decedents, nonresponders, known genetic diagnoses, mosaicism), ≥1 outcomes were noted in 83% of 77 participants following RoR; 78% had a process outcome (referral to a specialist, new testing, surveillance initiated); 68% had an intermediate outcome (new test finding or diagnosis); 19% had a clinical outcome (therapy modified, risk reduction surgery). Risk reduction surgery occurred more often in participants with tier 1 than those with non–tier 1 variants.
Relevant phenotypic traits were observed in 57% whereas a clinical outcome occurred in 19% of participants with actionable genomic variants in the year following RoR.
Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Data is deposited in dbGaP (accession code phs001616.v2.p2) at website https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001616.v2.p2.
Feero, W. G., Wicklund, C. A. & Veenstra, D. Precision medicine, genome sequencing, and improved population health. JAMA. 319, 1979–1980 (2018).
ACMG Board of Directors. The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 21, 1467–1468 (2019).
Hosseini, S. M. et al. Reappraisal of reported genes for sudden arrhythmic death: Evidence-based evaluation of gene validity for Brugada syndrome. Circulation. 138, 1195–1205 (2018).
Natarajan, P. et al. Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. Sci. Transl. Med. 8, 364ra151 (2016).
Shah, N. et al. Identification of misclassified ClinVar variants via disease population prevalence. Am. J. Hum. Genet. 102, 609–619 (2018).
Wright, C. F. et al. Assessing the pathogenicity, penetrance, and expressivity of putative disease-causing variants in a population setting. Am. J. Hum. Genet. 104, 275–286 (2019).
Khoury, M. J. No shortcuts on the long road to evidence-based genomic medicine. JAMA. 318, 27–28 (2017).
Jones, L. K. et al. Healthcare utilization and patients’ perspectives after receiving a positive genetic test for familial hypercholesterolemia. Circ. Genom. Precis. Med. 11, e002146 (2018).
Buchanan, A. H. et al. Clinical outcomes of a genomic screening program for actionable genetic conditions. Genet. Med. 22, 1874–1882 (2020).
Williams, J. L. et al. Harmonizing outcomes for genomic medicine: comparison of eMERGE outcomes to ClinGen outcome/intervention pairs. Healthcare (Basel). 6, 83 (2018).
Hart, M. R. et al. Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genet. Med. 21, 1100–1110 (2019).
Vassy, J. L. et al. The impact of whole-genome sequencing on the primary care and outcomes of healthy adult patients: a pilot randomized trial. Ann. Intern. Med. 167, 159–169 (2017).
Kalia, S. S. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 19, 249–255 (2017).
eMERGE Clinical Annotation Working Group. Frequency of genomic secondary findings among 21,915 eMERGE network participants. Genet. Med. 22, 1470–1477 (2020).
Kullo, I. J. et al. The Return of Actionable Variants Empirical (RAVE) study, a Mayo Clinic genomic medicine implementation study: design and initial results. Mayo Clin Proc 93, 1600–1610 (2018).
Dotson, W. D. et al. Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin. Pharmacol. Ther. 95, 394–402 (2014).
von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 370, 1453–1457 (2007).
Olson, J. E. et al. The Mayo Clinic Biobank: a building block for individualized medicine. Mayo Clin. Proc. 88, 952–962 (2013).
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
Kochan, D. C. et al. Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study. NPJ Genomic Med. 5, 19 (2020).
ACMG Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet. Med. 17, 68–69 (2015).
Harris, P. A. et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).
Williams, M. S. Early lessons from the implementation of genomic medicine programs. Annu. Rev. Genomics Hum. Genet. 20, 389–411 (2019).
Peterson, J. F. et al. Building evidence and measuring clinical outcomes for genomic medicine. Lancet. 394, 604–610 (2019).
Shaibi, G. Q. et al. Returning genomic results in a federally qualified health center: the intersection of precision medicine and social determinants of health. Genet. Med. 22, 1552–1559 (2020).
US Centers for Disease Control and Prevention. Tier 1 genomics applications and their importance to public health. https://www.cdc.gov/genomics/implementation/toolkit/tier1.htm (2019).
Gallego, C. J. et al. Penetrance of hemochromatosis in HFE genotypes resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network. Am. J. Hum. Genet. 97, 512–520 (2015).
Khoury, M. J. et al. Correction: A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health. PLoS Med. 15, e1002650 (2018).
Manickam, K. et al. Exome sequencing-based screening for BRCA1/2 expected pathogenic variants among adult biobank participants. JAMA Netw. Open. 1, e182140 (2018).
Johnston, J. J. et al. Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutations. Am. J. Hum. Genet. 96, 913–925 (2015).
Haer-Wigman, L. et al. 1 in 38 individuals at risk of a dominant medically actionable disease. Eur. J. Hum. Genet. 27, 325–330 (2019).
Youngblom, E. et al. in GeneReviews. (eds Adam, M. P., Ardinger, H. H., Pagon, R. A., et al.) Familial hypercholesterolemia (University of Washington, Seattle, 2016).
Petrucelli, N., Daly, M. B. & Pal, T. in GeneReviews (eds Adam, M. P., Ardinger, H. H., Pagon, R. A., et al.) BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (University of Washington, Seattle, 2016).
Kohlmann, W. & Gruber, S. B. in GeneReviews (eds Adam, M. P., Ardinger, H. H., Pagon, R. A., et al.) Lynch syndrome (University of Washington, Seattle, 2018).
Møller, P. et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 66, 464–472 (2017).
Senter, L. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 135, 419–428 (2008).
Van Driest, S. L. et al. Association of arrhythmia-related genetic variants with phenotypes documented in electronic medical records. JAMA. 315, 47–57 (2016).
Grosse, S. D. & Khoury, M. J. What is the clinical utility of genetic testing? Genet. Med. 8, 448–450 (2006).
Dorschner, M. O. et al. Actionable, pathogenic incidental findings in 1,000 participants’ exomes. Am. J. Hum. Genet. 93, 631–640 (2013).
Patel, A. P. et al. Association of rare pathogenic DNA variants for familial hypercholesterolemia, Hereditary breast and ovarian cancer syndrome, and Lynch syndrome with disease risk in adults according to family history. JAMA Netw. Open. 3, e203959 (2020).
Doble, B., Schofield, D. J., Roscioli, T. & Mattick, J. S. Prioritising the application of genomic medicine. NPJ Genomic Med. 2, 35 (2017).
Zhang, L. et al. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genet. Med. 21, 1958–1968 (2019).
McMurry, A. J. et al. SHRINE: enabling nationally scalable multi-site disease studies. PLoS One. 8, e55811 (2013).
The RAVE study was funded as part of the NHGRI-supported eMERGE (Electronic Records and Genomics) Network (U01HG006379) and by the Mayo Center for Individualized Medicine. I.J.K. was additionally funded by K24 HL137010.
RAVE study candidates were asked to complete a study consent form and health questionnaires, and provide a blood sample (if an existing sample was not available) to participate in this study. This study and the informed consent process were approved by the Mayo Institutional Review Board. Information about the Mayo Clinic Biobank’s collection and enrollment methods are described here: https://pubmed.ncbi.nlm.nih.gov/24001487/.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lee, C., Elsekaily, O., Kochan, D.C. et al. Penetrance and outcomes at 1-year following return of actionable variants identified by genome sequencing. Genet Med (2021). https://doi.org/10.1038/s41436-021-01142-9